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New activities for the anti-tumor agent trabectedin: taking two 
birds with one stone
Maurizio D’Incalci, Roberta Frapolli, Giovanni Germano and Paola Allavena
In the last decade the neoplastic cell-centric 
paradigm is now changing in a stroma-centric paradigm, 
focusing on the tumor micro-environment. This is 
populated by inflammatory leukocytes, activated 
fibroblasts and newly formed vessels, which influence 
each other in a complex and dynamic cross-talk with 
neoplastic cells.  It is now established that in most cancers 
Tumor-Associated Macrophages (TAM) display pro-
tumor functions (e.g. increase tumor cell proliferation 
and survival, aid tumor cell dissemination, promote 
angiogenesis and matrix remodelling) [1-3]. Particular 
emphasis in cancer therapy has been put in combination 
strategies to attack both tumor cells and the stroma. We 
have recently reported in a paper published in Cancer Cell 
in February 2013 that the anti-tumor agent trabectedin 
has important modulatory effects on the tumor micro-
environment [4].
Trabectedin is an anti-tumor compound registered 
in Europe and in several other countries, for the second 
line treatment of soft tissue sarcoma (STS) and for ovarian 
cancer in combination with liposomal doxorubicin [5-
7]. This compound was originally extracted from a 
marine organism, the Tunicate Ecteinascidia, and is 
now synthetically produced by the Spanish company 
PharmaMar. Trabectedin is a minor groove DNA 
binder able to efficiently block cancer cell proliferation. 
However, this is only part of its several mechanisms of 
action; further studies, revealed inhibition on the activity 
of selected transcription factors, which translate - among 
other effects - in the reduced production of several 
inflammatory mediators like the chemokines CCL2 and 
CXCL8, the cytokine IL-6 and the angiogenic factor 
VEGF [8].
An effect on the micro-environment was suspected 
by the clinical evidence of atypical patterns of response: 
for instance, in patients with liposarcoma, a decrease in 
Figure 1: The anti-tumor agent trabectedin has direct effects on tumor cells, blocking cell cycle and proliferation. It 
also interferes with DNA repair mechanisms and with the activity of selected transcription factors (TF). At the level of the tumor micro-
environment trabectedin is cytotoxic to monocytes and Tumor-Associated Macrophages (TAM); inhibits angiogenesis and the production 
of several inflammatory mediators.
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tumor density may occur without tumor shrinkage for 
several courses, eventually resulting in size decrease. In 
other patients, clinical responses take place only after 
several cycles of therapy. Indeed, STS patients have 
less than 10% responses (by RECIST criteria) but up 
to 50% stable disease and long overall survival [6-7]. A 
particularly high susceptibility to trabectedin has been 
observed in translocated-related soft tissue sarcoma. In 
myxoid liposarcoma, whose pathogenesis is related to a 
balanced translocation most commonly t(12;16)(q13;q12) 
fusing the FUS gene with the CHOP gene, trabectedin 
induces a prolonged response with a decrease in the 
vascular network and adipocytic differentiation in a large 
fraction of patients [7]. The FUS-CHOP chimera alters the 
transcription of several genes including some encoding 
for proteins involved in pro-inflammatory and angiogenic 
networks and in the repression of adipocytic maturation; 
indeed, the exquisite antitumor activity of trabectedin 
seems to be related to its ability to inhibit the aberrant 
transcription factor FUS-CHOP [5].  
In the Cancer Cell paper [4] we have used 
trabectedin in different mouse tumor models and 
investigated its effects on the tumor micro-environment, 
more specifically on leukocytes, angiogenesis, and on 
the expression of inflammatory mediators. We found that 
in treated mice trabectedin significantly decreased the 
number of blood monocytes and of tumor macrophages, 
having direct cytotoxic effects on this lineage, but not 
on other leukocyte subsets, such as neutrophils and 
lymphocytes (Fig. 1). We further demonstrated that treated 
tumors had a reduced vessel network. Similar results were 
found in human STS samples from patients receiving 
trabectedin as neo-adjuvant therapy: a marked decrease in 
blood vessels and in the tumor infiltrating macrophages. 
Using human liposarcoma xenografts grown in nude mice, 
we observed also a significant decrease in the expression 
of relevant mediators such as CCL2 and CXCL8 [8].
Overall, this compound has two major targets: it 
directly inhibits the neoplastic compartment but also 
affects the tumor micro-environment, in particular the 
macrophages and their pro-tumoral functions.
Trabectedin is currently used to treat a limited 
number of tumor types, and as second line therapy. Our 
findings that trabectedin has wider mechanism of action 
and strikes the whole micro-environment may stimulate 
its use in less advanced neoplastic settings and in tumors 
of different histology.
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